CN1191829C - 稳定的庚铂溶液制剂 - Google Patents
稳定的庚铂溶液制剂 Download PDFInfo
- Publication number
- CN1191829C CN1191829C CN 03121174 CN03121174A CN1191829C CN 1191829 C CN1191829 C CN 1191829C CN 03121174 CN03121174 CN 03121174 CN 03121174 A CN03121174 A CN 03121174A CN 1191829 C CN1191829 C CN 1191829C
- Authority
- CN
- China
- Prior art keywords
- platinum
- heptan
- pharmaceutical solutions
- malonic acid
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- LQSPYTDDQJPNCW-UHFFFAOYSA-N C(CCCCCC)[Pt] Chemical compound C(CCCCCC)[Pt] LQSPYTDDQJPNCW-UHFFFAOYSA-N 0.000 title abstract 3
- 239000000243 solution Substances 0.000 claims abstract description 20
- 230000006641 stabilisation Effects 0.000 claims abstract description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 70
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 35
- 229910052697 platinum Inorganic materials 0.000 claims description 35
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 28
- 239000003186 pharmaceutical solution Substances 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 238000001914 filtration Methods 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 12
- 230000001954 sterilising effect Effects 0.000 claims description 10
- -1 alkali metal salt Chemical class 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- 229910052783 alkali metal Inorganic materials 0.000 claims description 8
- QILMIEMHJSZECS-UHFFFAOYSA-N [Pt].CCCCCCC Chemical compound [Pt].CCCCCCC QILMIEMHJSZECS-UHFFFAOYSA-N 0.000 claims description 7
- PRWXGRGLHYDWPS-UHFFFAOYSA-L sodium malonate Chemical compound [Na+].[Na+].[O-]C(=O)CC([O-])=O PRWXGRGLHYDWPS-UHFFFAOYSA-L 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 238000004659 sterilization and disinfection Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 abstract description 6
- 239000007924 injection Substances 0.000 abstract description 6
- 230000000118 anti-neoplastic effect Effects 0.000 abstract description 3
- 230000003139 buffering effect Effects 0.000 abstract description 2
- XJXKGUZINMNEDK-GPJOBVNKSA-L [(4r,5r)-5-(aminomethyl)-2-propan-2-yl-1,3-dioxolan-4-yl]methanamine;platinum(2+);propanedioate Chemical compound [Pt+2].[O-]C(=O)CC([O-])=O.CC(C)C1O[C@H](CN)[C@@H](CN)O1 XJXKGUZINMNEDK-GPJOBVNKSA-L 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000005536 corrosion prevention Methods 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 229950006835 eptaplatin Drugs 0.000 abstract 1
- 238000005063 solubilization Methods 0.000 abstract 1
- 230000007928 solubilization Effects 0.000 abstract 1
- 238000011105 stabilization Methods 0.000 abstract 1
- 239000007788 liquid Substances 0.000 description 16
- 238000003756 stirring Methods 0.000 description 14
- 238000005352 clarification Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
- 239000003381 stabilizer Substances 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 8
- 239000008215 water for injection Substances 0.000 description 7
- 238000005262 decarbonization Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
- 229960004316 cisplatin Drugs 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 239000013505 freshwater Substances 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 239000012982 microporous membrane Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 239000002932 luster Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03121174 CN1191829C (zh) | 2003-03-28 | 2003-03-28 | 稳定的庚铂溶液制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03121174 CN1191829C (zh) | 2003-03-28 | 2003-03-28 | 稳定的庚铂溶液制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1439366A CN1439366A (zh) | 2003-09-03 |
CN1191829C true CN1191829C (zh) | 2005-03-09 |
Family
ID=27797236
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 03121174 Expired - Lifetime CN1191829C (zh) | 2003-03-28 | 2003-03-28 | 稳定的庚铂溶液制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1191829C (zh) |
-
2003
- 2003-03-28 CN CN 03121174 patent/CN1191829C/zh not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CN1439366A (zh) | 2003-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1138541C (zh) | 一种药学上稳定的奥沙利铂制剂 | |
CN1293916C (zh) | 稳定的胰岛素制剂 | |
CN1109754A (zh) | 阿尔加特罗邦浓缩水溶液 | |
CN85107562A (zh) | 含蒽环糖苷药物组合物的制备方法 | |
CN1686116A (zh) | 左旋奥硝唑的静脉给药制剂及其制备方法 | |
CN101439031A (zh) | 一种含18种氨基酸的药物组合物 | |
US11771773B2 (en) | Pharmaceutical preparation containing polyethylene gylcol loxenatide and preparation method thereof | |
CN1492760A (zh) | 环糊精制剂 | |
CN101073580A (zh) | 复合维生素注射液及其制备方法 | |
CN1283235C (zh) | 清澈稳定的丙泊酚组合物 | |
CN102335123A (zh) | 重酒石酸去甲肾上腺素注射液及其制剂工艺 | |
JP2023014110A (ja) | ホスファプラチン液体製剤 | |
CN1650883A (zh) | 盐酸吉西他滨溶液型注射剂 | |
JP2008525136A (ja) | オキサリプラチン用プラスチック瓶 | |
CN1191829C (zh) | 稳定的庚铂溶液制剂 | |
CN1830440A (zh) | 一种甲硝唑注射液及其制备方法和用途 | |
CN1931874A (zh) | 人参糖肽的制备方法、药物制剂及医药用途 | |
CN1897940A (zh) | 用于非经肠胃给药的长春氟宁医药组合物及其制备方法和用途 | |
CN1954811A (zh) | 奥沙利铂静脉注射剂及其制备方法 | |
CN1429558A (zh) | 甘露聚糖肽注射液及其制备方法和使用方法 | |
CN1493283A (zh) | 具有良好稳定性的注射用依达拉奉粉针剂及其制备方法 | |
CN101491495B (zh) | 丹酚酸b镁注射剂、制备方法及应用 | |
CN1830428A (zh) | 一种阿魏酸钠注射液及其制备方法和用途 | |
CN1864666A (zh) | 甲磺酸左氧氟沙星冻干粉针注射剂及其制备方法 | |
RU2241488C1 (ru) | Раствор даларгина для инъекций |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20030903 Assignee: Yang Yifang Assignor: He Guangwei Contract record no.: 2014320000370 Denomination of invention: Stable heptyl platinum solution preparation Granted publication date: 20050309 License type: Common License Record date: 20140430 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20151116 Address after: 230088, F8 building, 3, Hefei hi tech Zone Venture Center, Anhui Patentee after: HEFEI YIGONG MEDICINE Co.,Ltd. Address before: 230031 No. 820 West Changjiang Road, Anhui, Hefei Patentee before: He Guangwei |
|
CP03 | Change of name, title or address |
Address after: 230088 No. 2127, D8 Building, No. 800 Wangjiangxi Road, Hefei City, Anhui Province Patentee after: HEFEI INDUSTRIAL PHARMACEUTICAL INSTITUTE Co.,Ltd. Address before: 230088 3rd Floor, F8 Building, Venture Center, Hefei High-tech Zone, Anhui Province Patentee before: HEFEI YIGONG MEDICINE Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
CX01 | Expiry of patent term |
Granted publication date: 20050309 |
|
CX01 | Expiry of patent term |